Abstract:Objective To systematically review the effectiveness of Shengxuening tablet for renal anemia. Methods We electronically searched databases including Pubmed, Web of Science, VIP, WanFang Data and CNKI for published articles of randomized controlled trials (RCTs) of Shengxuening tablets versus other drugs and conventional drugs for renal anemia from inception to August 2017. According to the inclusion and exclusion criteria, two reviewers independently screened literature, extracted data and assessed the risk of bias in included studies. Then, Meta-analyses was performed with Stata 12.0 software. Results A total of 17 RCTs involving 1193 patients with renal anemia were included. The results of Meta-analyses showed that the improvement of laboratory indications, such as Hemoglobin [WMD = 1.52, 95%CI (1.18, 1.86), P < 0.001], Hematocrit [WMD = 1.90, 95%CI (1.19, 2.60), P < 0.001], Serum Ferritin [WMD = 2.01, 95%CI (1.38, 2.65), P < 0.001] and Transferrin Saturation [WMD = 1.90, 95%CI (1.30, 2.50), P < 0.001]. Conclusion The current evidence shows that Shengxuening tablet may significantly improve the effectiveness. Due to the limited quality and quantity of the included studies, the above conclusions need more high quality studies to verify.
刘巧艳 陈帆 曹世义▲. 生血宁片治疗肾性贫血临床效果的Meta分析[J]. 中国医药导报, 2018, 15(4): 120-125.
LIU Qiaoyan CHEN Fan CAO Shiyi▲. Effectiveness of Shengxuening tablet in the treatment of renal anemia: a Meta-analysis. 中国医药导报, 2018, 15(4): 120-125.
[1] 黄宇虹,邓晟,何作瑜.肾性贫血的药物治疗研究进展[J].山东医药,2011,51(39):109-111.
[2] 孙云.左卡尼汀与肾性贫血的相关研究[D].济南:山东大学,2015.
[3] 甘良英,王梅.K/DOQI关于慢性肾脏病贫血治疗的临床实践指南解读[J].中国血液净化,2008,7(8):455-458.
[4] 李佳桓,林海红,杜钢军.生血宁抗红细胞衰老及对再生障碍性贫血的治疗作用[J].中药材,2017,40(2):446-451.
[5] 田生望,肖乾秀,季业伟,等.叶绿素及其衍生物的实验与临床研究简析[J].中华中医药学刊,2004,22(2):286-288.
[6] 骆丹东,傅小玲,王江潮.生血宁治疗缺铁性贫血的临床疗效与观察[J].中华全科医学,2015,13(2):225-226.
[7] 张林,姜丹,甘晓辉.铁叶绿酸钠治疗缺铁性贫血的安全性及有效性的系统评价[J].贵阳中医学院学报,2013,35(5):45-49.
[8] 张学忠,徐燕丽,金娟,等.中药生血宁加环孢菌素A治疗慢性再生障碍性贫血的临床观察[J].中国中西医结合杂志,2006,26(8):684-684.
[9] 张磊,张文锦,金华,等.生血宁治疗肾性贫血的有效性与安全性Meta分析[J].临床肾脏病杂志,2015,15(6):353-358.
[10] 王海燕.肾脏病学[M].人民卫生出版社,2008.
[11] 张颖兰,李小军,胡琼丹,等.生血宁片治疗血液透析患者肾性贫血的临床观察[J].大家健康:学术版,2012,6(18):45-47.
[12] 周瑾,郭风玲,董巧荣,等.生血宁片治疗糖尿病肾病腹膜透析患者肾性贫血的疗效[J].中国老年学,2016,36(21):5383-5384.
[13] 谭锦萍,文素娟,关瑞云,等.生血宁治疗58例肾性贫血临床效果分析[J].中国医疗前沿,2013,8(9):37-38.
[14] 马晓辉,李晓刚.生血宁与硫酸亚铁治疗肾性贫血的疗效比较[J].贵阳中医学院学报,2014,36(3):59-60.
[15] 龙利,伍艳玲,卢远航,等.生血宁片治疗慢性肾脏病非透析患者肾性贫血的临床观察[J].长春中医药大学学报,2012,36(3):504-506.
[16] 程新.生血宁片和琥珀酸亚铁治疗血液透析肾性贫血疗效对比观察[J].中国卫生标准管理,2015,6(21):103-104.
[17] 梁鸿卿,胡韬韬,陈芳.生血宁治疗腹膜透析患者贫血的临床观察[J].中国保健营养:临床医学学刊,2008,42(9):71-73.
[18] 荆婷婷.生血宁片和多糖铁复合物胶囊两种口服铁剂在治疗维持性血液透析患者肾性贫血中的治疗效果评价[J].中国卫生标准管理,2015,6(26):121-122.
[19] 张娟,吴小燕.生血宁片治疗维持性腹膜透析患者肾性贫血的临床观察[J].临床肾脏病杂志,2016,16(8):492-495.
[20] 徐华庆.生血宁辅助治疗44例血液透析患者肾性贫血疗效观察[J].中国初级卫生保健,2012,31(5):128-129.
[21] 曾玲玲,屈燧林.生血宁片联合促红细胞生成素和左卡尼汀治疗肾性贫血的临床研究[J].现代药物与临床,2016, 31(5):678-682.
[22] 黄勇,王秀君.双倍剂量瑞克生血宁治疗慢性肾脏病3-4期肾性贫血的疗效[J].包头医学院学报,2016,32(11):75-76.
[23] Cheng X,Yu G,Hu J,et al. Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients [J]. Exp Ther Med,2016,12(1):157-160.
[24] 张蕖,苏超,崔丽,等.生血宁联合促红细胞生成素治疗血液透析患者肾性贫血的疗效[J].安徽医学,2017,38(4):453-455.
[25] 秦鹏,厉珊.生血宁片联合促红细胞生成素治疗肾性贫血的体会[J].中国保健营养:临床医学学刊,2009,43(2):94-95.
[26] 周长岳.生血宁联合促红细胞生成素治疗肾性贫血76例临床观察[J].中国民族民间医药,2010,19(22):105.
[27] 李红波,熊飞.生血宁片联合促红细胞生成素治疗腹膜透析患者贫血的疗效观察[J].中国现代医药杂志,2010, 12(11):96-97.
[28] 荆婷婷,胡江平,程新,等.生血宁片联合促红细胞生成素(EPO)治疗肾性贫血的临床观察[J].中国卫生标准管理,2015,6(21):105-106.
[29] 姜红红,康廷国,孟宪生,等.生血宁片中Fe元素的形态分析方法研究[J].广东微量元素科学,2010,17(9):38-42.
[30] 程新,于国俊,胡江平,等.生血宁片联合促红细胞生成素干预血液透析患者肾性贫血的临床初探[J].系统医学,2016,1(1):77-80.
[31] Fleming RE,Sly WS. Hepcidin:a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease [J]. Proceedings of the National Academy of Sciences of the United States of America,2001,98(15):8160.
[32] Ruchala P,Nemeth E. The pathophysiology and pharmacology of hepcidin[J].Trends in Pharmacological Sciences,2014,35(3):155-161.
[33] Jr BA,Corradini E,Xia Y,et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism [J]. Nature Genetics,2009,41(4):482-487.
[34] Canali S,Zumbrennen-Bullough KB,Core AB,et al. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice [J]. Blood,2017,129(4):405-414.
[35] Pietrangelo A,Dierssen U,Valli L,et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo [J]. Gastroenterology,2007,132(1):294-300.
[36] 黄劲华.奥美拉唑联合阿莫西林、甲硝唑对消化性溃疡进行治疗的临床效果观察[J].中国社区医师:医学专业,2013,15(8):71-72.
[37] 李佳桓,林海红,杜钢军.生血宁对肾性贫血和铁过载慢性肾损伤小鼠的防治作用[J].河南大学学报:自然版,2017,47(2):170-176.
[38] 柯有甫.国家科技进步二等奖药物生血宁片药效与安全再评价[J].医药前沿,2011,1(19):38-39.
[39] 汪勤,吴瑜,罗京,等.生血宁一般生殖毒性的实验研究[J].湖北中医杂志,2009,31(8):70-71.
[40] 魏克民,柯有甫,浦锦宝,等.蚕砂提取物研制中药Ⅱ类新药生血宁片[J].医学研究通讯,2003,34(8):20.